The partnership targets neuroimmune and CNS disorders using Insilico's Pharma.AI engine, with $18 million in upfront payments and milestone-based upside.
The alliance extends Insilico's PandaOmics and Chemistry42 platforms into pharmaceutical manufacturing for the first time, targeting a $168B CDMO industry.